Apricus Biosciences, Inc. was pleased to announce earlier today that its wholly owned subsidiary, NexMed USA, has received clearance from the U.S. Food and Drug Administration to market its second, over-the-counter anti-itch drug, Hydrocortisone-D(TM).
“This is the second clearance by the FDA of a drug containing Apricus Bio’s NexACT(R) drug delivery technology, and as such, enhances our strategy of building out our OTC products division and creating a new revenue-generating portfolio for the Company,” commented Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus Bio.”
Apricus Bio’s newly cleared OTC product combines hydrocortisone with DDAIP, the main ingredient in NexACT(R), the company’s proprietary drug delivery technology. NexACT temporarily loosens the tight junctions between skin cells to allow more permeation.
“Since January we have been working on building out our OTC portfolio. With Tolnaftate-D(TM) having been cleared last week and Hydrocortisone-D(TM) coming in this week, we are creating a new division that can contribute to both near-term revenues and long-term growth,” stated Dr. Damaj.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
Apricus Biosciences, Inc. (APRI) Granted FDA Clearance for Second OTC Anti-Itch Drug Containing NexACT Technology
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.